GlassScriptPhysician profile
Kayla D Gee
NPI 1083955231
$1,885.10
in general payments reported to CMS, 2019-2025
22 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $516 · 2023: $493 · 2024: $419 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $373.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $365.23 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $204.68 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.75 | 2021-2025 | Jardiance |
| Ferring Pharmaceuticals INC. | $92.68 | 2021-2022 | |
| Pfizer INC. | $90.45 | 2022-2025 | |
| Inspire Medical Systems, INC. | $84.16 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $78.06 | 2022-2023 | Shingrix, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $64.37 | 2023-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $59.94 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Exact Sciences Corporation | $48.40 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $41.23 | 2022 | |
| Dexcom, INC. | $39.70 | 2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $33.20 | 2024 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.88 | 2024-2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $28.13 | 2022-2024 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $26.70 | 2024 | Rexulti |
| Aimmune Therapeutics, INC. | $19.61 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.55 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.06 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.